Trial Details
Single-Dose, Phase 1b Study to Assess Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects With Mild to Moderate Spasticity Due to Cerebral Palsy
NCT01405950
TERMINATED
DESCRIPTION
A Single-Dose, Phase 1b, Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in Pediatric Subjects 2 to 16 Years Old With Mild to Moderate Spasticity Due to Cerebral Palsy.
CONDITIONS
Spasticity Due to Cerebral Palsy
ELIGIBILITY CRITERIA
- Inclusion Criteria
- :
- Have clinically diagnosed spasticity resulting from cerebral palsy
- Have a motor disability resulting from a static, nonprogressive brain injury or malformation occurring prenatally or before the age of 2 years
- Have mild to moderate spasticity at screening
- Have a parent or legally accepted representative able to understand and comply with study requirements who voluntarily provides informed consent and agrees to be primarily responsible for adhering to the requirements of the study
- Exclusion Criteria
- :
- Have a history of hypersensitivity or allergic reaction to tizanidine or any of the capsule components
- Have dietary restrictions or food allergies that conflict with a standardized meal
- Have clinically significant psychiatric, gastrointestinal, pulmonary, hematologic, endocrine, cardiovascular, renal, or hepatic disease that requires pharmacologic intervention
- Have an ongoing seizure disorder that requires medical therapy
